
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant is a promising company with a potential first-in-class FcRn inhibitor in Difficult-to-Treat RA. The company has a strong pipeline with multiple upcoming catalysts, including potential registrational trial data for IMVT-1402 in GD and MG. The company's current financial situation is solid with sufficient funding to support ongoing operations and potential commercial launch of IMVT-1402. Risks to achieving the price target include regulatory and clinical, COVID-19 impact, and competition in the market.
Bears say
Immunovant is facing potential risks in their upcoming Phase 2 study, as the high efficacy in Period 1 may make Period 2 statistically riskier, potentially hindering their chances of gaining FDA approval. Additionally, the ongoing period 2 study, combined with one more pivotal trial, may not be sufficient for registration, risking delays in bringing their potential treatment to market. With a lack of other significant sources of revenue, the success of their lead product is crucial to the company's financial stability and future growth.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares